Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells

Endocrinology

Volumn 145, Issue 12, 2004, Pages 5745-5756

  Simoncini, Tommaso ^a   Mannella, Paolo ^a   Fornari, Letizia ^a   Caruso, Antonella ^a   Willis, Monica Y ^a   Garibaldi, Silvia ^a   Baldacci, Chiara ^a   Genazzani, Andrea R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CONJUGATED ESTROGEN; ESTRADIOL; GESTAGEN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MEDROXYPROGESTERONE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE; TRANSCRIPTION FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

AORTA; ARTICLE; CARDIOVASCULAR SYSTEM; CELL ADHESION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SYNTHESIS; TRANSCRIPTION REGULATION;

CELL COMMUNICATION; CELLS, CULTURED; CONTRACEPTIVE AGENTS, FEMALE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ESTRADIOL; HUMANS; LEUKOCYTES; MEDROXYPROGESTERONE 17-ACETATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OVARIECTOMY; PHOSPHORYLATION; PROGESTERONE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UMBILICAL VEINS;

EID: 9444234576     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-0510     Document Type: Article

References (54)

1. Mendelsohn ME, Karas RH 1999 The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801-1811
2. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; the Women's Health Initiative Investigators 2003 Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523-534
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 280:605-613
4. The Women's Health Initiative Steering Committee 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial. JAMA 291:1701-1712
5. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K 1997 Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 3:324-327
6. Register TC, Adams MR, Golden DL, Clarkson TB 1998 Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 18:1164-1171
7. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB 1990 Inhibition of coronary artery atherosclerosis by 17-β estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10:1051-1057
8. Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, de Ziegler D, Collins P 2000 Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 36:2154-2159
9. Nilsen J, Brinton RD 2002 Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 143:205-212
10. Nilsen J, Brinton RD 2003 Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci USA 100:10506-10511
11. Speroff L, Glass RH, Kase NG 1999 Clinical gynecologic endocrinology and infertility. 6th ed. Baltimore: Lippincott Williams & Wilkins
12. Hiroi M, Stanczyk FZ, Goebelsmann U, Brenner PF, Lumkin ME, Mishell Jr DR 1975 Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration. Steroids 26:373-386
13. Sitruk-Ware R 2004 Pharmacological profile of progestins. Maturitas 47: 277-283
14. Ross R 1999 Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126
15. Xing D, Miller A, Novak L, Rocha R, Chen YF, Oparil S 2004 Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 109:234-241
16. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kishimoto T, Kasayama S 2001 Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 21:243-248
17. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani AR 2003 In vitro effects of progesterone and progestins on vascular cells. Steroids 68:831-836
18. Simoncini T, Apa R, Reis FM, Miceli F, Stomati M, Driul L, Lanzone A, Genazzani AR, Petraglia F 1999 Human umbilical vein endothelial cells: a new source and potential target for corticotropin-releasing factor. J Clin Endocrinol Metab 84:2802-2806
19. Knowles RG, Salter M 1998 Measurement of NOS activity by conversion of radiolabeled arginine to citrulline using ion-exchange separation. In: Titheradge MA, ed. Nitric oxide protocols. Totowa, NJ: Humana Press; 67-73
20. Simoncini T, Genazzani AR 2000 Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 85:2966-2969
21. Simoncini T, Hafezi-Moghadam A, Brazil D, Ley K, Chin WW, Liao JK 2000 Interaction of estrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538-541
22. Simoncini T, Maffei S, Basta G, Barsacchi G, Genazzani AR, Liao JK, De Caterina R 2000 Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ Res 87:19-25
23. Pober J, Gimbrone MJ, Lapierre L, Mendrick D, Fiers W, Rothlein R, Springer T 1986 Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 137:1893-1896
24. Dignam JD, Lebovitz RM, Roeder RG 1983 Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475-1489
25. Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T 1992 Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med 176:1583-1593
26. Kloosterboer HJ, Deckers GH, Schoonen WG 1994 Pharmacology of two new very selective antiprogestogens: Org 31710 and Org 31806. Hum Reprod 9(Suppl 1):47-52
27. Simoncini T, Varone G, Fornari L, Mannella P, Luisi M, Labrie F, Genazzani AR 2002 Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology 143:2052-2061
28. Simoncini T, Genazzani AR 2003 Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148:281-292
29. Simoncini T, Rabkin E, Liao JK 2003 Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 23:198-203
30. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM 1999 Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-605
31. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC 1999 Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399:597-601
32. McDonnell DP 2003 Mining the complexities of the estrogen signaling pathways for novel therapeutics. Endocrinology 144:4237-4240
33. Li X, O'Malley BW 2003 Unfolding the action of progesterone receptors. J Biol Chem 278:39261-39264
34. Sitruk-Ware R 2002 Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 9:6-15
35. Zhang R, Min W, Sessa WC 1995 Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem 270:15320-15326
36. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB 1998 Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 273:10696-10701
37. da Silva Santos Duarte A, Sales TS, Mengel JO, Costa FF, Saad ST 2002 Progesterone upregulates GATA-1 on erythroid progenitors cells in liquid culture. Blood Cells Mol Dis 29:213-224
38. Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Forstermann U 1998 Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension 31:582-588
39. Chambliss KL, Shaul PW 2002 Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 23:665-686
40. Chataigneau T, Zerr M, Chataigneau M, Hudlett F, Hint C, Pernot F, Schini-Kerth VB 2004 Chronic treatment with progesterone but not medroxyprogesterone acetate restores the endothelial control of vascular tone in the mesenteric artery of ovariectomized rats. Menopause 11:255-263
41. Hafezi-Moghadam A, Simoncini T, Yang E, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK 2002 Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8:473-479
42. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR 2003 Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 144:3449-3455
43. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F 2001 PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 20:6050-6059
44. Bagowski CP, Myers JW, Ferrell Jr JE 2001 The classical progesterone receptor associates with p42 MAPK and is involved in phosphatidylinositol 3-kinase signaling in Xenopus oocytes. J Biol Chem 276:37708-37714
45. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the estrogen receptor. Nature 389:753-758
46. Ballare C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A, Auricchio F, Beato M 2003 Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 23:1994-2008
47. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M 1995 Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270:286-290
48. Narita T, Kawakami-Kimura N, Matsuura N, Hosono J, Kannagi R 1995 Corticosteroids and medroxyprogesterone acetate inhibit the induction of E-selectin on the vascular endothelium by MDA-MB-231 breast cancer cells. Anticancer Res 15:2523-2527
49. Elovitz M, Wang Z 2004 Medroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine fetal demise. Am J Obstet Gynecol 190:693-701
50. Mueck AO, Seeger H, Wallwiener D 2002 Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause 9:273-281
51. Sorensen MB, Collins P, Ong PJL, Webb CM, Hayward CS, Asbury EA, Gatehouse PD, Elkington AG, Yang GZ, Kubba A, Pennell DJ 2002 Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 106:1646-1651
52. Koh KK, Jin DK, Yang SH, Lee SK, Hwang HY, Kang MH, Kim W, Kim DS, Choi IS, Shin EK 2001 Vascular effects of synthetic or natural progestogen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 103:1961-1966
53. McNeill AM, Zhang C, Stanczyk FZ, Duckles SP, Krause DN 2002 Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke 33:1685-1691
54. Dinh H, Nathan L 2002 Medroxyprogesterone acetate does not antagonize estrogen-induced increases in endothelium-dependent vasodilation: potential clinical implications. Fertil Steril 78:122-127